These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27771366)

  • 1. Molecular targeting of hypoxia in radiotherapy.
    Rey S; Schito L; Koritzinsky M; Wouters BG
    Adv Drug Deliv Rev; 2017 Jan; 109():45-62. PubMed ID: 27771366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.
    Meijer TW; Kaanders JH; Span PN; Bussink J
    Clin Cancer Res; 2012 Oct; 18(20):5585-94. PubMed ID: 23071360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can we overcome tumor hypoxia in radiation therapy?
    Harada H
    J Radiat Res; 2011; 52(5):545-56. PubMed ID: 21952313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors.
    Leung E; Cairns RA; Chaudary N; Vellanki RN; Kalliomaki T; Moriyama EH; Mujcic H; Wilson BC; Wouters BG; Hill R; Milosevic M
    BMC Cancer; 2017 Jun; 17(1):418. PubMed ID: 28619042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced nanomaterials targeting hypoxia to enhance radiotherapy.
    Li J; Shang W; Li Y; Fu S; Tian J; Lu L
    Int J Nanomedicine; 2018; 13():5925-5936. PubMed ID: 30319257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Autonomous Metabolic Reprogramming in Hypoxia.
    Schito L; Rey S
    Trends Cell Biol; 2018 Feb; 28(2):128-142. PubMed ID: 29191366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
    Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
    J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxic pathobiology of breast cancer metastasis.
    Schito L; Rey S
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):239-245. PubMed ID: 28526262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia as a biomarker for radioresistant cancer stem cells.
    Peitzsch C; Perrin R; Hill RP; Dubrovska A; Kurth I
    Int J Radiat Biol; 2014 Aug; 90(8):636-52. PubMed ID: 24844374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment.
    Moeller BJ; Richardson RA; Dewhirst MW
    Cancer Metastasis Rev; 2007 Jun; 26(2):241-8. PubMed ID: 17440683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of hypoxia in radiation oncology: pathophysiology, tumor biology and implications for treatment.
    Busk M; Horsman MR
    Q J Nucl Med Mol Imaging; 2013 Sep; 57(3):219-34. PubMed ID: 24045619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
    Shi M; Guo XT; Shu MG; Chen FL; Li LW
    Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to overcome (and exploit) tumor hypoxia for targeted gene therapy.
    Greco O; Marples B; Joiner MC; Scott SD
    J Cell Physiol; 2003 Dec; 197(3):312-25. PubMed ID: 14566961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation and hypoxia inducible gene therapy systems.
    Scott SD; Greco O
    Cancer Metastasis Rev; 2004; 23(3-4):269-76. PubMed ID: 15197328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome.
    Kim JY; Lee JY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hypoxia and the metabolic microenvironment on radiotherapy of solid tumors. Introduction of a multi-institutional research project.
    Zips D; Adam M; Flentje M; Haase A; Molls M; Mueller-Klieser W; Petersen C; Philbrook C; Schmitt P; Thews O; Walenta S; Baumann M
    Strahlenther Onkol; 2004 Oct; 180(10):609-15. PubMed ID: 15480508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor hypoxia in cancer therapy.
    Brown JM
    Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-directed drug strategies to target the tumor microenvironment.
    Hay MP; Hicks KO; Wang J
    Adv Exp Med Biol; 2014; 772():111-45. PubMed ID: 24272357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors.
    Wouters A; Boeckx C; Vermorken JB; Van den Weyngaert D; Peeters M; Lardon F
    Curr Pharm Des; 2013; 19(5):907-17. PubMed ID: 22973959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.